Kanamitsu Kiichiro, Chayama Kousuke, Washio Kana, Yoshida Ryuichi, Umeda Yuzo, Yagi Takahito, Shimada Akira
Department of Pediatrics, Okayama University Hospital, Okayama 700-8558, Japan.
Acta Med Okayama. 2018 Oct;72(5):515-518. doi: 10.18926/AMO/56250.
Hepatitis-associated aplastic anemia (HAAA) is an acquired bone marrow failure syndrome that develops after seronegative fulminant hepatitis. Abnormal cytotoxic T-cell activation with cytokine release is a possible pathophysiology. We present the case of a 16-month-old Japanese male who developed HAAA following living-donor liver transplantation for fulminant hepatitis. His aplastic anemia was successfully treated with immunosuppressive therapy. He had been administered tacrolimus for prophylaxis against hepatic allograft rejection. Ten years after the HAAA onset, the patient's bone marrow was found to be slightly hypoplastic. Tacrolimus may be effective in controlling abnormal immune reactions that can cause recurrent impaired hematopoiesis.
肝炎相关性再生障碍性贫血(HAAA)是一种在血清学阴性暴发性肝炎后发生的获得性骨髓衰竭综合征。细胞毒性T细胞异常激活并释放细胞因子可能是其病理生理学机制。我们报告一例16个月大的日本男性病例,该患者在因暴发性肝炎接受活体供肝移植后发生了HAAA。他的再生障碍性贫血通过免疫抑制治疗成功治愈。他曾接受他克莫司预防肝移植排斥反应。HAAA发病十年后,发现患者骨髓轻度增生低下。他克莫司可能对控制可导致反复造血功能受损的异常免疫反应有效。